Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Paraneoplastic Syndromes, Nervous System

ClinicalTrials.gov lists 388 trials for Paraneoplastic Syndromes, Nervous System or a narrower condition beneath it. Alexion Pharmaceuticals, Inc. has the most among industry and government lead sponsors, with 20.

MeSH D020361 Neoplasms Neoplasm C04 C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 40 Phase 1/2 Phase 1/2 11 Phase 2 Phase 2 45 Phase 2/3 Phase 2/3 14 Phase 3 Phase 3 77 Phase 4 Phase 4 9 Not applicable Not applicable 56 Observational Observational 128 Phase 1 Phase 1 40 Phase 1/2 Phase 1/2 11 Phase 2 Phase 2 45 Phase 2/3 Phase 2/3 14 Phase 3 Phase 3 77 Phase 4 Phase 4 9 Not applicable Not applicable 56 Observational Observational 128

Trials per phase

1 more section with rows

1 of the 388 trials are tagged with Paraneoplastic Syndromes, Nervous System itself; the rest are tagged with a narrower condition beneath it.

Get the Paraneoplastic Syndromes, Nervous System report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Paraneoplastic Syndromes, Nervous System trials start? (29)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 54

1993: 1 trials (Not applicable 1) 1994: 1 trials (Not applicable 1) 1995: 4 trials (Observational 2, Not applicable 1, Phase 3 1) 1997: 1 trials (Other 1) 2001: 2 trials (Phase 4 2) 2002: 3 trials (Observational 1, Phase 3 1, Phase 1 1) 2004: 4 trials (Phase 3 2, Phase 1/2 1, Phase 1 1) 2005: 3 trials (Other 1, Phase 2 1, Phase 1/2 1) 2006: 4 trials (Observational 1, Phase 3 3) 2007: 3 trials (Observational 1, Phase 4 1, Phase 3 1) 2008: 4 trials (Observational 1, Phase 2 3) 2009: 4 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 2 1) 2010: 4 trials (Observational 1, Not applicable 1, Phase 2 1, Phase 1 1) 2011: 7 trials (Not applicable 1, Phase 3 3, Phase 2 2, Phase 1 1) 2012: 5 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 1, Phase 1 1) 2013: 5 trials (Observational 3, Phase 3 2) 2014: 13 trials (Observational 5, Not applicable 1, Phase 3 3, Phase 2 4) 2015: 10 trials (Observational 2, Not applicable 2, Phase 3 2, Phase 2 4) 2016: 10 trials (Observational 3, Not applicable 2, Phase 3 2, Phase 2 1, Phase 1/2 1, Phase 1 1) 2017: 11 trials (Observational 7, Phase 2 2, Phase 1 2) 2018: 11 trials (Observational 1, Not applicable 3, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 1) 2019: 23 trials (Observational 8, Not applicable 3, Phase 3 7, Phase 2/3 1, Phase 2 4) 2020: 22 trials (Observational 12, Not applicable 1, Phase 3 2, Phase 2/3 1, Phase 2 4, Phase 1 2) 2021: 23 trials (Observational 10, Not applicable 2, Phase 3 9, Phase 2/3 1, Phase 2 1) 2022: 29 trials (Observational 8, Not applicable 8, Phase 3 5, Phase 2/3 3, Phase 2 3, Phase 1/2 1, Phase 1 1) 2023: 29 trials (Observational 12, Not applicable 8, Phase 3 5, Phase 2/3 1, Phase 2 1, Phase 1 2) 2024: 54 trials (Observational 19, Not applicable 8, Phase 4 1, Phase 3 10, Phase 2/3 5, Phase 2 4, Phase 1/2 2, Phase 1 5) 2025: 43 trials (Observational 12, Not applicable 3, Phase 4 2, Phase 3 7, Phase 2/3 1, Phase 2 1, Phase 1/2 2, Phase 1 15)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 49
2025 43
2024 54
2023 29
2022 29
2021 23
2020 22
2019 23
2018 11
2017 11

Showing 10 of 29 earlier years.

Start your 14-day trial Email me all 29 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 60 trials starting in 2026 and about 50 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 69 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 167 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Paraneoplastic Syndromes, Nervous System trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 40
Phase 1/2 11
Phase 2 45
Phase 2/3 14
Phase 3 77
Phase 4 9
Not applicable 56
Observational 128
Expanded access 8

How many Paraneoplastic Syndromes, Nervous System trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 33
Recruiting 105
Enrolling by invitation 9
Active, not recruiting 24
Completed 137

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Paraneoplastic Syndromes, Nervous System trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Alexion Pharmaceuticals, Inc. 20
argenx 17
UCB Biopharma SRL 14
Catalyst Pharmaceuticals, Inc. 5

Which drugs are being tested for Paraneoplastic Syndromes, Nervous System? (11)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Efgartigimod 16
3, 4-Diaminopyridine 13
RITUXIMAB 10
Rozanolixizumab 10
Zilucoplan 9

Showing 5 of 11 drugs.

Start your 14-day trial Email me all 11 drugs as a PDF

Interventions as named in the registry (4)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Efgartigimod PH20 (ARGX-113) SC 4
GC012F Injection 3
data collection 3
IR Tacrolimus 3

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Paraneoplastic Syndromes, Nervous System trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Myasthenia gravis 170 23
Pneumonia 57 19
Myasthenia gravis crisis 52 16
Neuromyelitis optica spectrum disorder 49 3
COVID-19 34 12

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Paraneoplastic Syndromes, Nervous System? (14)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies. Journal of neurology, neurosurgery, and psychiatry 2018 Yes
Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens. Archives of neurology 2012 Yes
Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 2010 Yes
Reversible extralimbic paraneoplastic encephalopathies with large abnormalities on magnetic resonance images. Archives of neurology 2009 Yes
Paraneoplastic syndromes of the CNS. The Lancet. Neurology 2008 Yes

Showing 5 of 14 publications.

Start your 14-day trial Email me all 14 publications as a PDF

Prevalence (2)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Paraneoplastic neurologic syndrome Point prevalence Unknown Worldwide Not stated Exact
Paraneoplastic neurologic syndrome Point prevalence Unknown Worldwide Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Paraneoplastic neurologic syndrome 36388 Exact Orphanet Rare Disease Ontology (ORDO)
Paraneoplastic neurologic syndrome 36388 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (7)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages